imatinib mesylate has been researched along with Pleural Effusion in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 14 (50.00) | 24.3611 |
| 2020's | 5 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| Du, X; Jin, J; Liu, P; Lou, J; Meng, L; Wang, W; Yu, W | 1 |
| Cai, J; Huang, J; Jiang, Q; Lin, H; Wu, L; Ye, Q | 1 |
| Gupta, SK; Kumar, N; Tripathi, AK; Verma, SP | 1 |
| Aoyama, T; Imai, S; Kashiwagi, H; Kuriyama, H; Sato, Y; Sugawara, M; Takekuma, Y | 1 |
| Asmis, T; Gilbert, S; Pysyk, CL | 1 |
| Bakanay, SM; Dilek, I; Kucuksahin, O; Maral, S | 1 |
| Aman, J; Peters, MJ; van Nieuw Amerongen, GP; Vonk Noordegraaf, A; Weenink, C | 1 |
| Ai, HS; Dong, Z; Guo, M; Hu, KX; Li, BX; Qiao, JH; Sun, QY; Yao, B; Yu, CL; Zhang, ZC | 1 |
| Ai, HS; Qaio, JH; Zhang, ZC | 1 |
| Cortes, JE; Hochhaus, A; le Coutre, P; Mohamed, H; Mustjoki, S; Porkka, K; Saglio, G; Schiffer, CA; Shah, NP | 1 |
| Cortes, JE; Healey, D; Hochhaus, A; Kantarjian, H; Milone, J; Mohamed, H; Rea, D; Rousselot, P; Saglio, G; Schiffer, C; Shah, NP | 1 |
| Chiba, S; Hagihara, M; Igarashi, T; Inokuchi, K; Iriyama, N; Kawakami, K; Kouzai, Y; Kumagai, T; Morita, S; Ohyashiki, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Taguchi, J; Takezako, N; Wakita, H; Yano, S; Yoshida, C | 1 |
| Jing, Y; Lu, N; Yang, L; Yu, L | 1 |
| Bilmes, R; Lin, J; Lingohr-Smith, M; Makenbaeva, D | 1 |
| Bergeron, A; Cony-Makhoul, P; Corm, S; Dubruille, V; Nicolini, FE; Rea, D; Rigal-Huguet, F | 1 |
| Giles, FJ; Kelly, K; Mahalingam, D; Padmanabhan, S; Swords, R | 1 |
| Brigid Bradley-Garelik, M; Bullorsky, E; Charbonnier, A; Dombret, H; Ehninger, G; Larson, RA; Lilly, MB; Martinelli, G; Müller, MC; Ottmann, OG; Reiffers, JJ; Shah, NP; Zhu, C | 1 |
| Akiyama, H; Fukuda, S; Kobayashi, T; Nagata, Y; Ohashi, K; Sakamaki, H; Yamashita, T | 1 |
| Haba, Y; Hanzawa, K; Itoyama, S; Kizaki, M; Mori, S; Nemoto, T; Sagawa, M; Saito, Y; Sekiguchi, Y; Tamaru, J; Tokuhira, M; Tomikawa, A; Watanabe, R | 1 |
| Alimena, G; Breccia, M | 1 |
| Thachil, J | 1 |
| Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L | 1 |
| Audring, H; Baskaynak, G; Dörken, B; Kreuzer, KA; le Coutre, P; Riess, H; Schwarz, M; Zuber, J | 1 |
| Alimena, G; Breccia, M; D'Andrea, M; D'Elia, GM; Latagliata, R | 1 |
| Aksu, S; Beyazit, Y; Goker, H; Haznedaroglu, IC; Kekilli, M; Kilickap, S | 1 |
| Ishii, Y; Kimura, Y; Ohyashiki, K; Shoji, N | 1 |
| Countouriotis, A; Golenkov, A; Hamerschlak, N; Hellmann, A; Holowiecki, J; Hughes, T; Jootar, S; Kantarjian, H; Khoroshko, N; Masszi, T; Pasquini, R; Radich, J; Robak, T; Rousselot, P; Shah, N; Skotnicki, A; Zaritsky, A | 1 |
| Borthakur, G; Bruzzi, J; Cortes, J; Kantarjian, H; Munden, R; O'brien, S; Quintás-Cardama, A | 1 |
2 review(s) available for imatinib mesylate and Pleural Effusion
| Article | Year |
|---|---|
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
Topics: Benzamides; Cell Proliferation; Cytotoxicity, Immunologic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Pericardial Effusion; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Serositis; Thiazoles; Treatment Outcome | 2009 |
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Comorbidity; Dasatinib; Disease Management; Drug Administration Schedule; Drug Eruptions; Humans; Hypercholesterolemia; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Pericardial Effusion; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles; Treatment Outcome | 2010 |
5 trial(s) available for imatinib mesylate and Pleural Effusion
| Article | Year |
|---|---|
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Topics: Antineoplastic Agents; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Pancytopenia; Patient Safety; Pleural Effusion; Protein Kinase Inhibitors; Treatment Outcome | 2016 |
Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.
Topics: Adult; Aged; Aged, 80 and over; Dasatinib; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors | 2016 |
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; src-Family Kinases; Thiazoles; Young Adult | 2010 |
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Drug Resistance; Edema; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pancytopenia; Piperazines; Pleural Effusion; Pyrimidines; Salvage Therapy; Thiazoles; Treatment Outcome | 2007 |
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Administration Schedule; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Pleural Effusion; Pyrimidines; Radiography; Risk Factors; Thiazoles; Treatment Failure | 2007 |
21 other study(ies) available for imatinib mesylate and Pleural Effusion
| Article | Year |
|---|---|
Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China.
Topics: Antineoplastic Agents; Dasatinib; Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Pleural Effusion; Prospective Studies; Protein Kinase Inhibitors; Treatment Outcome | 2022 |
Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
Topics: Adverse Drug Reaction Reporting Systems; Chylothorax; Dasatinib; Female; Humans; Imatinib Mesylate; Pericardial Effusion; Pharmacovigilance; Pleural Effusion; Pulmonary Edema; Pyrimidines; Retrospective Studies; United States; United States Food and Drug Administration | 2023 |
Case reports of chronic myeloid leukemia and tuberculosis: Is imatinib the link between the two?
Topics: Adult; Antineoplastic Agents, Immunological; Causality; Dasatinib; Drug Substitution; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mycobacterium tuberculosis; Pleural Effusion; Protein Kinase Inhibitors; Treatment Outcome; Tuberculosis, Central Nervous System; Tuberculosis, Pleural | 2021 |
cAMP Signaling Pathway Prevents Dasatinib-Induced Vascular Hyperpermeability.
Topics: Aniline Compounds; Antigens, CD; Cadherins; Capillary Permeability; Cell Culture Techniques; Cyclic AMP; Dasatinib; Endothelial Cells; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Permeability; Pleural Effusion; Protein Kinase Inhibitors; Quinolines; Signal Transduction | 2021 |
Pleural and pericardial effusions in patient on tyrosine kinase inhibitor.
Topics: Aged; Female; Humans; Imatinib Mesylate; Neoplasms; Pericardial Effusion; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2018 |
Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.
Topics: Dasatinib; Echocardiography; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lupus Erythematosus, Systemic; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines | 2020 |
Reversal of vascular leak with imatinib.
Topics: Benzamides; Female; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pulmonary Edema; Pyrimidines; Vascular Diseases | 2013 |
[Clinical efficacy of switching to 2nd generation of tyrosine kinase inhibitor on CML patients at poor responses to imatinib].
Topics: Benzamides; Blast Crisis; Cytogenetics; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome | 2015 |
[A case report of refractory pleural effusion associated with dasatinib in the treatment of chronic myeloied leukemia].
Topics: Dasatinib; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pleural Effusion; Prognosis; Recurrence; Remission Induction | 2015 |
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Incidence; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphocytosis; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; T-Lymphocytes, Cytotoxic | 2016 |
[Chylothorax Related with Dasatinib in the Treatment of Chronic Myeloid Leukemia: Report of 3 Cases].
Topics: Chylothorax; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pleural Effusion; Prognosis; Protein Kinase Inhibitors | 2016 |
Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dasatinib; Female; Health Services; Humans; Imatinib Mesylate; Insurance Claim Review; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Economic; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Vascular Diseases; Young Adult | 2017 |
[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Dasatinib; Drug Resistance, Neoplasm; Female; France; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pregnancy; Pyrimidines; Thiazoles | 2008 |
Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Substance Withdrawal Syndrome; Thiazoles | 2010 |
[Acute-onset eosinophilic leukemia associated with tumor lysis syndrome after imatinib and steroid pulse therapy].
Topics: Acute Kidney Injury; Aged, 80 and over; Benzamides; Disseminated Intravascular Coagulation; Drug Synergism; Fatal Outcome; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Eosinophilic, Acute; Methylprednisolone; Piperazines; Pleural Effusion; Pulse Therapy, Drug; Pyrimidines; Tumor Lysis Syndrome | 2010 |
Adverse effects of imatinib--dissecting heart from the rest.
Topics: Antineoplastic Agents; Benzamides; Edema; Heart Failure; Humans; Imatinib Mesylate; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes | 2011 |
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan | 2002 |
Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment.
Topics: Age Factors; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cocarcinogenesis; Coronary Disease; Drug Eruptions; Dyspnea; Enzyme Inhibitors; Facial Neoplasms; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Pancytopenia; Piperazines; Pleural Effusion; Pyrimidines; Sunlight; Ultraviolet Rays | 2003 |
Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pericardial Effusion; Piperazines; Pleural Effusion; Pyrimidines | 2005 |
Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Blood Cell Count; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphatic Diseases; Middle Aged; Piperazines; Pleural Effusion; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Middle Aged; Philadelphia Chromosome; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Radiography | 2006 |